Indication
Chronic lymphocytic leukemia
8 clinical trials
10 products
2 drugs
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2022-10-27
Product
ObinutuzumabProduct
AcalabrutinibProduct
rituximabClinical trial
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-05-03
Product
ABT-263Clinical trial
A Phase 3 Multicentre, Randomized, Prospective, Open-label Trial of Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Status: Active (not recruiting), Estimated PCD: 2027-03-01
Product
IbrutinibProduct
VenetoclaxClinical trial
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL PatientsStatus: Active (not recruiting), Estimated PCD: 2016-12-13
Product
BendamustineProduct
GA101Product
ABT-199Clinical trial
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG Protocol)Status: Active (not recruiting), Estimated PCD: 2025-04-01
Drug
ZanubrutinibClinical trial
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab), Acalabrutinib (ACP-196) and ABT-199 (Venetoclax) in Patients With Relapsed/Refractory CLL (CLL2-BAAG Protocol)Status: Completed, Estimated PCD: 2021-02-11
Clinical trial
Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL PatientsStatus: Completed, Estimated PCD: 2022-03-09
Product
CAL-101Clinical trial
CLL-Frail - A Prospective, Multicenter Phase II Trial of Acalabrutinib in Very Old (≥80y) or Frail CLL-PatientsStatus: Active (not recruiting), Estimated PCD: 2023-07-31
Drug
Varlilumab